吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GILD 吉利德科学

交易中 09-09 15:58:01 EDT

145.60

-1.04

-0.71%

最高147.68	最低145.00	成交量263.39万
今开145.46	昨收146.64	日振幅1.83%
总市值1,806亿	流通市值1,803亿	总股本12.41亿
成交额3.84亿	换手率0.21%	流通股本12.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":145.6,"timestamp":1788983881663,"preClose":146.64,"halted":0,"volume":2633896,"delay":0,"changeRate":-0.00709219858156023,"floatShares":1238162880,"shares":1240679623,"eps":-2.614993,"marketStatus":"交易中","change":-1.04,"latestTime":"09-09 15:58:01 EDT","open":145.46,"high":147.68,"low":145,"amount":384168665.79032004,"amplitude":0.018276,"askPrice":145.61,"askSize":408,"bidPrice":145.59,"bidSize":534,"shortable":3,"etf":0,"ttmEps":-2.614993,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1788984000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":696056400000,"exchange":"NASDAQ","adjPreClose":146.64,"dividendRate":0.022115,"preHourTrading":{"tag":"盘前","latestPrice":144.4,"preClose":146.64,"latestTime":"09:27 EDT","volume":1777,"amount":258742.62610999998,"timestamp":1788960470033,"change":-2.24,"changeRate":-0.015276,"amplitude":0.029594},"postHourTrading":{"tag":"盘后","latestPrice":146.56,"preClose":146.64,"latestTime":"19:35 EDT","volume":740261,"amount":108551300.2415,"timestamp":1788910557155,"change":-0.08,"changeRate":-0.000546,"amplitude":0.000682},"volumeRatio":0.497218,"impliedVol":0.2913,"impliedVolPercentile":0.3108},"requestUrl":"/m/hq/s/GILD","defaultTab":"news","newsList":[{"id":"1136308873","title":"Assembly Biosciences有望获得高达2.8亿美元里程碑付款及美国境外特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136308873?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","LU0965509010.AUD","LU1934455277.USD","LU2324357040.USD","LU0823416689.USD","LU0058720904.USD","LU1585245621.USD","LU0114720955.EUR","SG9999015952.SGD","LU2087621335.USD","LU2089984988.USD","LU0965508806.USD","LU1061106388.HKD","LU1571399168.USD","LU0889565916.HKD","BMED","LU0965509101.SGD","BK4585","LU0320765992.SGD","LU0861579265.USD","IBBQ","IE00B3T34201.USD","LU0882574055.USD","LU1066051498.USD","MEDI","SG9999015945.SGD","LU1674673428.USD","TBXU","LU0965509283.SGD","LU2357627491.SGD","IBB","BK4550","LU0234570918.USD","LU0289739699.SGD","BK4583","BK4588","GILD","BBH","BK4532","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU0122379950.USD","LU0859254822.USD","LU1037948897.HKD","TMED","BK4578","BK4566","SG9999015986.USD","LU0109394709.USD","LU1066053197.SGD","LU1037948541.HKD","ASMB","BIB","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","LU1778281490.HKD","IE0002270589.USD","LU1934455863.HKD","LU1023059063.AUD","SG9999015978.USD","LU1057294990.SGD","LU1934455194.USD","BK4139","LU2112291526.USD","LU1430594728.SGD","BK4568","LU1839511570.USD","IE00BKVL7J92.USD","LU2468319806.SGD","LU1674673691.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179预计2026年底前将推进至生殖器疱疹二期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154623157?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","LU0965509010.AUD","LU1934455277.USD","LU2324357040.USD","LU0823416689.USD","LU0058720904.USD","LU1585245621.USD","LU0114720955.EUR","SG9999015952.SGD","LU2087621335.USD","LU2089984988.USD","LU0965508806.USD","LU1061106388.HKD","LU1571399168.USD","LU0889565916.HKD","BMED","LU0965509101.SGD","BK4585","LU0320765992.SGD","LU0861579265.USD","IBBQ","IE00B3T34201.USD","LU0882574055.USD","LU1066051498.USD","MEDI","SG9999015945.SGD","LU1674673428.USD","TBXU","LU0965509283.SGD","LU2357627491.SGD","IBB","BK4550","LU0234570918.USD","LU0289739699.SGD","BK4583","BK4588","GILD","BBH","BK4532","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU0122379950.USD","LU0859254822.USD","LU1037948897.HKD","TMED","BK4578","BK4566","SG9999015986.USD","LU0109394709.USD","LU1066053197.SGD","LU1037948541.HKD","ASMB","BIB","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","LU1778281490.HKD","IE0002270589.USD","LU1934455863.HKD","LU1023059063.AUD","SG9999015978.USD","LU1057294990.SGD","LU1934455194.USD","BK4139","LU2112291526.USD","LU1430594728.SGD","BK4568","LU1839511570.USD","IE00BKVL7J92.USD","LU2468319806.SGD","LU1674673691.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德独享HSV HPI项目临床开发与商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115029168?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","LU0965508806.USD","LU1037948897.HKD","IE00B19Z3581.USD","LU1066051498.USD","LU2112291526.USD","BK4583","BK4585","BK4532","BIB","LU1066053197.SGD","LU1674673428.USD","TBXU","LU1023059063.AUD","LU1037948541.HKD","BK4588","BK4578","LU0882574055.USD","LU1778281490.HKD","LU2087621335.USD","MEDI","LU2468319806.SGD","ASMB","LU1934455277.USD","IBBQ","LU0058720904.USD","IE00BSNM7G36.USD","LU1934455863.HKD","GILD","IBB","LU0823416689.USD","LU1585245621.USD","LU2089984988.USD","SG9999015986.USD","LU1674673691.USD","BK4550","LU0122379950.USD","LU1934455194.USD","LU0114720955.EUR","TMED","BK4566","SG9999015978.USD","IE0002270589.USD","SG9999015945.SGD","LU1430594728.SGD","BBH","LU0965509283.SGD","LU1061106388.HKD","IE00BKVL7J92.USD","LU1057294990.SGD","LU2324357040.USD","LU2357627491.SGD","LU0320765992.SGD","BK4568","LU0859254822.USD","BK4139","SG9999015952.SGD","IE00BZ1G4Q59.USD","IE00B3T34201.USD","LU0234570918.USD","LU0861579265.USD","LU0889565916.HKD","LU1571399168.USD","LU0965509101.SGD","LU0289739699.SGD","IE00B7SZLL34.SGD","LU0965509010.AUD","LU1839511570.USD","IE00B19Z3B42.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使与吉利德关于HSV解旋酶-引物酶抑制剂项目的美国利润分成选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179230759?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU0114720955.EUR","BK4568","IE00B19Z3B42.SGD","LU1066053197.SGD","LU1430594728.SGD","LU0823416689.USD","BIB","LU1037948897.HKD","SG9999015945.SGD","LU1023059063.AUD","LU0289739699.SGD","BMED","SG9999015978.USD","LU0965509010.AUD","BK4588","LU0889565916.HKD","LU1674673691.USD","BK4585","ASMB","LU0234570918.USD","LU1057294990.SGD","LU0122379950.USD","LU1934455863.HKD","IE00B7SZLL34.SGD","LU2468319806.SGD","BBH","IE00BSNM7G36.USD","BK4583","MEDI","LU1585245621.USD","IBBQ","TBXU","TMED","IE00B3T34201.USD","SG9999015952.SGD","LU1934455194.USD","GILD","LU2087621335.USD","LU0965509101.SGD","LU1061106388.HKD","LU1778281490.HKD","SG9999015986.USD","LU0861579265.USD","LU0109394709.USD","LU2324357040.USD","BK4139","LU1674673428.USD","LU1571399168.USD","LU1934455277.USD","LU0859254822.USD","IBB","LU1066051498.USD","BK4566","BK4532","LU0320765992.SGD","LU2089984988.USD","BK4550","LU1839511570.USD","IE00BKVL7J92.USD","LU2357627491.SGD","LU0882574055.USD","BK4578","IE00B19Z3581.USD","LU0965508806.USD","LU0058720904.USD","IE00BZ1G4Q59.USD","LU2112291526.USD","LU1037948541.HKD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196773407","title":"异动解读｜吉利德科学盘中下跌3.18%，报148.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196773407","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196773407?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:44","pubTimestamp":1788875062,"startTime":"0","endTime":"0","summary":"9月8日，吉利德科学盘中下跌3.18%，报148.27美元/股，成交额3905.71万美元。吉利德科学所在的生物科技行业中，个股普遍承压，其中安进跌6.86%，Moderna跌2.15%，艾伯维公司跌1.03%，Ionis Pharmaceuticals跌3.05%，PDS Biotechnology涨161.55%。吉利德科学是一家以研究为基础的生物制药公司，主要聚焦病毒性疾病、炎性和纤维化疾病及肿瘤学领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165523116","title":"异动解读｜吉利德科学盘前下跌3.47%，报146.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165523116","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165523116?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:29","pubTimestamp":1788874147,"startTime":"0","endTime":"0","summary":"9月8日，吉利德科学盘前下跌3.47%，报146.39美元/股，成交额163.33万美元。吉利德科学所在的生物科技行业中，个股普遍承压，其中Moderna涨0.31%，艾伯维跌1.70%，安进跌6.69%，再生元制药跌1.17%，福泰制药跌2.95%。吉利德科学是一家以研究为基础的生物制药公司，主要聚焦病毒性疾病、炎性和纤维化疾病及肿瘤学领域。近期公司在产品审批方面动作频繁，8月底HIV新药Bixlenvo获FDA批准，Trodelvy在欧盟及美国先后获批用于三阴性乳腺癌一线治疗。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186632498","title":"欧盟委员会扩大吉利德Trodelvy®在转移性三阴性乳腺癌一线治疗中的应用范围，覆盖所有PD-L1状态","url":"https://stock-news.laohu8.com/highlight/detail?id=1186632498","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186632498?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:32","pubTimestamp":1787567559,"startTime":"0","endTime":"0","summary":"欧盟委员会近日作出重要决定，将吉利德科学（Gilead Sciences）旗下重磅药物Trodelvy®的适用范围进一步拓宽。此次调整聚焦于转移性三阴性乳腺癌的一线治疗领域，且不再受限于患者的PD-L1表达状态。这一举措意味着，无论生物标志物检测结果如何，符合条件的患者均有望从该疗法中获益。此举不仅为临床医生提供了更为灵活的用药选择，也标志着Trodelvy®在肿瘤治疗版图中的地位得到显著提升。吉利德科学方面对此表示积极回应，认为该批准将助力满足更多患者未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","SG9999015952.SGD","LU0109394709.USD","TBXU","LU2468319806.SGD","MEDI","BK4139","LU2089984988.USD","LU0882574055.USD","IE00B3T34201.USD","LU1934455277.USD","BK4583","IBB","BK4566","LU1066051498.USD","LU1061106388.HKD","LU1674673691.USD","LU2357627491.SGD","GILD","LU0058720904.USD","SG9999015945.SGD","SG9999015978.USD","LU1571399168.USD","BK4568","LU1057294990.SGD","BK4585","LU0289739699.SGD","BK4532","BBH","LU0889565916.HKD","LU1023059063.AUD","LU1778281490.HKD","LU1585245621.USD","LU0965509101.SGD","BK4588","BMED","LU2087621335.USD","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU0114720955.EUR","LU1839511570.USD","LU1934455863.HKD","LU2324357040.USD","LU1037948897.HKD","BK4550","LU0965508806.USD","LU0320765992.SGD","LU0823416689.USD","LU0234570918.USD","LU1037948541.HKD","IBBQ","IE00B19Z3B42.SGD","LU0861579265.USD","LU1066053197.SGD","LU1674673428.USD","IE00BZ1G4Q59.USD","LU0965509283.SGD","LU0965509010.AUD","LU1934455194.USD","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","IE0002270589.USD","LU0859254822.USD","SG9999015986.USD","LU2112291526.USD","TMED","IE00BSNM7G36.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193380081","title":"吉利德科学：欧盟批准Trodelvy联合Keytruda用于一线PD-L1阳性转移性三阴性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1193380081","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193380081?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:32","pubTimestamp":1787567533,"startTime":"0","endTime":"0","summary":"吉利德科学公司宣布，欧盟已正式授予其抗体药物偶联物Trodelvy与默沙东的Keytruda联合用药方案的上市许可。这一批准针对的是既往未经治疗的PD-L1阳性转移性三阴性乳腺癌患者群体。此项授权标志着该联合疗法在欧盟地区的临床可及性迈出关键一步，为这类侵袭性强、治疗选择有限的乳腺癌亚型患者提供了新的一线治疗选项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","GILD","BK4578","LU2089984988.USD","LU1057294990.SGD","IE00BKVL7J92.USD","BMED","IE00B7SZLL34.SGD","LU0965509283.SGD","LU1934455863.HKD","LU0882574055.USD","TBXU","LU1061106388.HKD","IE0002270589.USD","LU1585245621.USD","LU0114720955.EUR","TMED","LU0320765992.SGD","LU0965509010.AUD","BK4550","LU1674673691.USD","LU1778281490.HKD","LU1430594728.SGD","BK4139","LU1066051498.USD","SG9999015986.USD","LU1023059063.AUD","LU1037948897.HKD","BK4568","LU0965509101.SGD","LU1066053197.SGD","BK4583","MEDI","LU0889565916.HKD","IBB","LU0109394709.USD","LU2324357040.USD","BK4532","IE00B3T34201.USD","IE00BSNM7G36.USD","LU2468319806.SGD","LU0234570918.USD","IBBQ","LU2087621335.USD","SG9999015952.SGD","LU0861579265.USD","LU1934455277.USD","BK4585","LU0058720904.USD","BIB","LU0823416689.USD","BK4588","LU1839511570.USD","LU1037948541.HKD","SG9999015945.SGD","LU1934455194.USD","LU1674673428.USD","SG9999015978.USD","IE00B19Z3581.USD","LU0122379950.USD","IE00BZ1G4Q59.USD","LU0965508806.USD","LU1571399168.USD","LU2357627491.SGD","BK4566","IE00B19Z3B42.SGD","LU0289739699.SGD","BBH","LU0859254822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170485794","title":"异动解读｜吉利德科学盘中上涨3.07%，78亿美元收购Arcellx叠加Q2业绩超预期持续推升股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1170485794","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170485794?lang=zh_cn&edition=full","pubTime":"2026-08-21 23:46","pubTimestamp":1787327199,"startTime":"0","endTime":"0","summary":"8月21日，吉利德科学盘中上涨3.07%，报147.85美元/股，成交额2.28亿美元。消息面上，吉利德科学于8月18日宣布将以78亿美元股权价值收购癌症疗法研发公司Arcellx，每股支付115美元现金外加每股5美元或有价值权，较Arcellx上一交易日收盘价溢价87%，市场将此视为公司进一步强化肿瘤学管线的重大战略举措，收购消息公布以来持续提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"吉利德科学盘中上涨，78亿收购叠加业绩超预期","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112102407","title":"异动解读｜吉利德科学盘中上涨3.15%，78亿美元收购Arcellx持续提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1112102407","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112102407?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:51","pubTimestamp":1787147470,"startTime":"0","endTime":"0","summary":"8月19日，吉利德科学盘中上涨3.15%，报147.675美元/股，成交额1.01亿美元。消息面上，吉利德科学于8月18日宣布将以78亿美元股权价值收购癌症疗法研发公司Arcellx，每股支付115美元现金外加每股5美元或有价值权，较Arcellx上一交易日收盘价溢价87%，市场将此视为公司进一步强化肿瘤学管线的重大战略举措。此外，公司Q2营收78亿美元超市场预期，全年亏损指引收窄至每股0.30至0.65美元，优于分析师预估的每股亏损0.75美元，基本面改善叠加并购利好持续推升股价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158603682","title":"异动解读｜吉利德科学盘中上涨3.05%，宣布78亿美元收购Arcellx加码肿瘤管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1158603682","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158603682?lang=zh_cn&edition=full","pubTime":"2026-08-18 23:33","pubTimestamp":1787067194,"startTime":"0","endTime":"0","summary":"8月18日，吉利德科学盘中上涨3.05%，报143.155美元/股，成交额2.35亿美元。消息面上，吉利德科学周一宣布将以78亿美元股权价值收购癌症疗法研发公司Arcellx，每股支付115美元现金外加每股5美元或有价值权，较Arcellx上一交易日收盘价溢价87%。此举被视为吉利德进一步强化肿瘤学管线的战略举措。同时，公司最新季度财报显示营收78亿美元超预期，全年亏损指引亦收窄至每股0.30至0.65美元，优于市场预估。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137034601","title":"异动解读｜吉利德科学盘中下跌3.03%，Q2因收购研发费用转亏引发市场抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1137034601","media":"行情直击","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137034601?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:49","pubTimestamp":1785941362,"startTime":"0","endTime":"0","summary":"8月5日，吉利德科学盘中下跌3.03%，报131.15美元/股，成交额5.23亿美元。消息面上，公司于8月4日盘后公布第二季度业绩，营收78亿美元同比增长10%，调整后每股亏损6.75美元，均优于市场预期。然而，近期收购产生的每股9.08美元知识产权研发及税务费用使公司由盈转亏。此外，新冠药物Veklury销售额暴跌81%至2300万美元，全年预测从约6亿美元腰斩至约3亿美元。高管还透露，ACA税收补贴取消导致部分患者失去医保覆盖，Q2艾滋病治疗市场趋软。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"吉利德科学盘中下跌3.03%，Q2因收购研发费用转亏引发市场抛压","news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108157113","title":"吉利德科学高管：Q2艾滋病治疗市场趋软，ACA税收补贴取消致部分民众失去医保覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=1108157113","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108157113?lang=zh_cn&edition=full","pubTime":"2026-08-05 05:32","pubTimestamp":1785879128,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）高管在财报电话会议中透露，第二季度艾滋病治疗市场呈现疲软态势。究其原因，部分患者因《平价医疗法案》（ACA）税收补贴取消而失去保险计划，导致市场购买力下降，对整个行业形成冲击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","LU0114720955.EUR","LU2112291526.USD","SG9999015978.USD","LU0823416689.USD","IBB","LU1839511570.USD","BBH","LU1934455194.USD","SG9999015986.USD","IE0002270589.USD","LU1430594728.SGD","TMED","BK4532","IE00BKVL7J92.USD","BIB","IE00B19Z3B42.SGD","BK4568","LU0965509010.AUD","LU0965509283.SGD","LU1037948541.HKD","LU1057294990.SGD","LU1571399168.USD","LU1585245621.USD","LU2087621335.USD","LU1934455277.USD","GILD","BMED","IE00B7SZLL34.SGD","LU0109394709.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU1037948897.HKD","LU1023059063.AUD","IBBQ","LU0289739699.SGD","LU2324357040.USD","LU1778281490.HKD","SG9999015945.SGD","BK4588","IE00B3T34201.USD","LU1674673428.USD","LU2468319806.SGD","BK4566","LU0965509101.SGD","LU1066053197.SGD","LU1934455863.HKD","LU1674673691.USD","LU0122379950.USD","BK4583","SG9999015952.SGD","LU0234570918.USD","IE00BSNM7G36.USD","LU0320765992.SGD","LU0058720904.USD","LU1066051498.USD","BK4550","TBXU","LU0861579265.USD","LU1061106388.HKD","IE00BZ1G4Q59.USD","LU0882574055.USD","MEDI","LU2089984988.USD","BK4585","LU0965508806.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100032335","title":"吉利德科学高管：今年暂无计划进行大规模并购交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1100032335","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100032335?lang=zh_cn&edition=full","pubTime":"2026-08-05 05:12","pubTimestamp":1785877926,"startTime":"0","endTime":"0","summary":"吉利德科学公司高管在电话会议上表示，目前不预计今年会进行额外的大规模并购交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU1061106388.HKD","MEDI","BMED","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","IE0002270589.USD","LU0320765992.SGD","LU1057294990.SGD","LU0114720955.EUR","LU2324357040.USD","IE00B7SZLL34.SGD","LU0965508806.USD","LU1037948897.HKD","BK4139","LU0058720904.USD","LU1674673691.USD","LU1778281490.HKD","LU2089984988.USD","LU0965509010.AUD","LU2112291526.USD","LU1066051498.USD","BK4585","LU1839511570.USD","TMED","BK4578","BK4550","LU2468319806.SGD","LU0823416689.USD","SG9999015986.USD","BK4532","SG9999015952.SGD","BBH","LU2087621335.USD","BK4588","LU1430594728.SGD","LU1585245621.USD","LU0889565916.HKD","LU0289739699.SGD","SG9999015978.USD","TBXU","SG9999015945.SGD","IBBQ","LU1023059063.AUD","LU0861579265.USD","LU1066053197.SGD","LU0965509101.SGD","BK4568","BK4566","LU1037948541.HKD","LU0882574055.USD","IE00B19Z3581.USD","LU0965509283.SGD","LU1674673428.USD","LU1934455277.USD","LU1934455863.HKD","LU0234570918.USD","GILD","BIB","IE00B19Z3B42.SGD","LU1934455194.USD","LU0122379950.USD","LU0109394709.USD","LU1571399168.USD","IE00B3T34201.USD","BK4583","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657679605","title":"吉利德科学于2026年8月4日公布了2026年第二季度财务业绩。总收入同比增长10%达到78亿美元主要得益于不包括Vek","url":"https://stock-news.laohu8.com/highlight/detail?id=2657679605","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657679605?lang=zh_cn&edition=full","pubTime":"2026-08-05 05:10","pubTimestamp":1785877839,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B19Z3581.USD","LU1934455277.USD","BBH","SG9999015986.USD","LU1066051498.USD","LU1023059063.AUD","LU1778281490.HKD","IBB","IE00BSNM7G36.USD","LU0965509010.AUD","LU0882574055.USD","BK4583","LU0234570918.USD","BK4550","BK4585","LU0823416689.USD","LU0109394709.USD","BIB","LU0889565916.HKD","IE00BZ1G4Q59.USD","LU1674673428.USD","LU2089984988.USD","GILD","LU1061106388.HKD","MEDI","TBXU","LU2324357040.USD","LU2087621335.USD","LU1057294990.SGD","BK4568","IE00BKVL7J92.USD","IBBQ","LU0122379950.USD","BMED","LU0861579265.USD","LU1037948541.HKD","LU1839511570.USD","SG9999015978.USD","LU0058720904.USD","IE00B19Z3B42.SGD","LU2468319806.SGD","SG9999015952.SGD","LU0965508806.USD","LU1571399168.USD","LU0114720955.EUR","LU0965509283.SGD","LU1430594728.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567644","title":"吉利德科学公司因研发成本转亏，HIV药物销售提振营收","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567644","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657567644?lang=zh_cn&edition=full","pubTime":"2026-08-05 05:09","pubTimestamp":1785877740,"startTime":"0","endTime":"0","summary":"吉利德科学公司于美股周二收盘后公布业绩，第二季度营收增长，主要得益于HIV产品销售额的提升，但近期收购产生的新研发支出使公司整体转盈为亏。剔除某些一次性项目后，吉利德报告调整后每股亏损6.75美元。吉利德表示，本季度新冠治疗药物Veklury销售额下降81%，至2300万美元，主要因新冠住院率降低。公司将Veklury全年销售预测下调至约3亿美元，此前预期约为6亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-05/doc-inimezkr3752456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135051692","title":"吉利德高管在电话会议中宣布：全年HIV业务增长预期上调至9%-10%，此前指引为8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135051692","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135051692?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:42","pubTimestamp":1785876147,"startTime":"0","endTime":"0","summary":"吉利德（Gilead Sciences）高管在电话会议上透露，公司已将全年HIV业务增长预期上调至9%至10%的区间。这一调整较此前8%的增长指引显著提升，展现了公司对该业务领域强劲势头的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","BBH","LU0234570918.USD","LU2324357040.USD","SG9999015978.USD","LU1839511570.USD","BK4139","BMED","LU1934455194.USD","LU2112291526.USD","MEDI","TMED","BK4583","LU1934455277.USD","BK4588","LU0823416689.USD","LU0965509101.SGD","GILD","IE00BSNM7G36.USD","LU0320765992.SGD","BK4550","LU1674673691.USD","IE00B7SZLL34.SGD","LU0965509283.SGD","LU1037948897.HKD","LU1061106388.HKD","LU1585245621.USD","IBB","IE00BZ1G4Q59.USD","LU2087621335.USD","LU1571399168.USD","LU0058720904.USD","LU1066053197.SGD","IE00B19Z3581.USD","LU0882574055.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","LU1023059063.AUD","BK4568","IE00BKVL7J92.USD","LU2089984988.USD","BK4532","BK4578","IBBQ","LU1430594728.SGD","LU1066051498.USD","TBXU","LU1934455863.HKD","LU0122379950.USD","BIB","SG9999015945.SGD","BK4585","LU0965508806.USD","SG9999015952.SGD","LU2468319806.SGD","BK4566","LU1674673428.USD","LU0861579265.USD","IE00B3T34201.USD","LU1057294990.SGD","LU0109394709.USD","SG9999015986.USD","IE0002270589.USD","LU1778281490.HKD","LU0114720955.EUR","LU1037948541.HKD","LU0965509010.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145483121","title":"吉利德高管：距FDA PDUFA日期仅剩五个月，Anito-Cel细胞疗法上市筹备工作已全面启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1145483121","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145483121?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:42","pubTimestamp":1785876146,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）高管透露，针对其重磅细胞疗法Anito-Cel的上市准备工作已全面铺开，目前距离美国食品药品监督管理局（FDA）设定的PDUFA目标日期仅剩五个月时间。这一消息源自公司近期召开的电话会议。\n在会议中，高管进一步强调，公司正紧锣密鼓地推进各项筹备事项，以确保一旦获批，该疗法能够迅速进入市场。Anito-Cel作为一种前沿的细胞治疗产品，被视为吉利德在肿瘤学领域布局的关键一环。随着最终审批日期的临近，市场对这款疗法的商业化前景给予高度关注，而吉利德方面则展现出对既定时间表与执行能力的充分信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455277.USD","IBBQ","BK4550","LU1037948541.HKD","LU2089984988.USD","GILD","BIB","LU0861579265.USD","LU1585245621.USD","LU1934455863.HKD","SG9999015952.SGD","BMED","TBXU","LU0882574055.USD","BK4588","LU1061106388.HKD","LU0965509010.AUD","LU2112291526.USD","SG9999015945.SGD","LU1674673428.USD","IE00B19Z3581.USD","IE00B3T34201.USD","LU0114720955.EUR","LU0823416689.USD","IE00BZ1G4Q59.USD","IE0002270589.USD","BK4566","LU2087621335.USD","SG9999015978.USD","LU1066051498.USD","LU0320765992.SGD","BK4578","LU1571399168.USD","LU1057294990.SGD","SG9999015986.USD","BK4139","LU0289739699.SGD","LU0965509101.SGD","LU1023059063.AUD","MEDI","IE00B7SZLL34.SGD","LU1839511570.USD","TMED","LU0122379950.USD","LU1066053197.SGD","IBB","IE00BKVL7J92.USD","BK4532","LU1430594728.SGD","LU2324357040.USD","LU0058720904.USD","LU0234570918.USD","BK4568","LU0889565916.HKD","LU1778281490.HKD","LU1037948897.HKD","LU0109394709.USD","LU1934455194.USD","BBH","LU1674673691.USD","BK4583","LU2468319806.SGD","LU0965508806.USD","LU0965509283.SGD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163992816","title":"吉利德科学第二季度调整后每股收益-6.75美元，高于IBES预估-7.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163992816","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163992816?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:17","pubTimestamp":1785874678,"startTime":"0","endTime":"0","summary":"8月4日，吉利德科学（Gilead Sciences）公布第二季度产品销售额达76.27亿美元。第二季度调整后每股收益为-6.75美元，优于IBES预估的-7.24美元。","market":"hk","thumbnail":"https://static.tigerbbs.com/9e7ba54e8539d48dd315975babea7852","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9e7ba54e8539d48dd315975babea7852"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU1023059063.AUD","LU1037948897.HKD","IE0002270589.USD","GILD","LU0965509010.AUD","LU1839511570.USD","TMED","BK4578","BBH","LU1571399168.USD","LU1934455277.USD","LU1430594728.SGD","LU0320765992.SGD","LU2324357040.USD","LU0122379950.USD","LU2468319806.SGD","LU0965509101.SGD","LU1585245621.USD","SG9999015945.SGD","LU0234570918.USD","LU2089984988.USD","MEDI","IE00BSNM7G36.USD","LU1674673691.USD","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","TBXU","BK4532","LU1066051498.USD","IE00B3T34201.USD","LU1934455863.HKD","SG9999015978.USD","LU0058720904.USD","BIB","IE00BKVL7J92.USD","BMED","LU0823416689.USD","LU1061106388.HKD","LU2112291526.USD","LU1037948541.HKD","BK4566","LU1934455194.USD","LU0289739699.SGD","BK4585","SG9999015986.USD","LU1057294990.SGD","BK4550","LU0965509283.SGD","IBB","BK4588","LU0114720955.EUR","BK4568","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU0861579265.USD","BK4583","BK4139","LU0109394709.USD","LU1066053197.SGD","LU2087621335.USD","SG9999015952.SGD","LU0889565916.HKD","LU0965508806.USD","LU1674673428.USD","LU1778281490.HKD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108344321","title":"吉利德科学：季度调整后每股亏损6.75美元，反映近期收购带来的每股9.08美元知识产权研发及税务支出","url":"https://stock-news.laohu8.com/highlight/detail?id=1108344321","media":"美股速递","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108344321?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:04","pubTimestamp":1785873878,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）最新季度业绩揭晓。数据显示，公司调整后每股收益为-6.75美元。这一数字背后，折射出近期收购活动所产生的重大财务影响——具体而言，每股9.08美元的知识产权研发成本与税务费用被计入。这些支出，均与公司近期完成的收购交易紧密相关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","BK4585","LU0234570918.USD","LU0965509283.SGD","LU0965509101.SGD","IBBQ","LU1057294990.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1571399168.USD","TMED","BK4583","BK4550","IE00B3T34201.USD","GILD","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU1066051498.USD","LU1839511570.USD","IE0002270589.USD","LU1934455277.USD","LU1934455863.HKD","LU2112291526.USD","LU1674673428.USD","TBXU","LU0289739699.SGD","LU0882574055.USD","LU2089984988.USD","LU2468319806.SGD","BK4578","LU1037948897.HKD","LU1066053197.SGD","LU1778281490.HKD","LU1934455194.USD","SG9999015978.USD","BK4139","LU1585245621.USD","IE00B7SZLL34.SGD","LU0114720955.EUR","SG9999015945.SGD","IBB","LU0122379950.USD","BK4532","LU1037948541.HKD","LU0861579265.USD","LU1061106388.HKD","LU0823416689.USD","LU2087621335.USD","IE00BKVL7J92.USD","LU0889565916.HKD","BIB","LU2324357040.USD","IE00BSNM7G36.USD","SG9999015952.SGD","LU0320765992.SGD","LU0965508806.USD","SG9999015986.USD","BK4588","LU0058720904.USD","MEDI","LU1023059063.AUD","LU0109394709.USD","BMED","BK4568","LU1674673691.USD","LU1430594728.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":-0.0219},{"period":"1month","weight":0.1008},{"period":"3month","weight":0.2071},{"period":"6month","weight":0.0098},{"period":"1year","weight":0.2654},{"period":"ytd","weight":0.1947}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":-0.0094},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.15},{"period":"1year","weight":0.1805},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.044916},{"month":2,"riseRate":0.428571,"avgChangeRate":0.008369},{"month":3,"riseRate":0.514286,"avgChangeRate":-0.011268},{"month":4,"riseRate":0.514286,"avgChangeRate":0.009883},{"month":5,"riseRate":0.571429,"avgChangeRate":0.020601},{"month":6,"riseRate":0.628571,"avgChangeRate":0.02322},{"month":7,"riseRate":0.571429,"avgChangeRate":0.016506},{"month":8,"riseRate":0.571429,"avgChangeRate":0.03575},{"month":9,"riseRate":0.571429,"avgChangeRate":0.030325},{"month":10,"riseRate":0.529412,"avgChangeRate":0.003173},{"month":11,"riseRate":0.647059,"avgChangeRate":0.039736},{"month":12,"riseRate":0.382353,"avgChangeRate":0.010114}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}